{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:04:58Z","timestamp":1791669898884,"version":"4.3.4"},"reference-count":62,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2022,7,1]]},"abstract":"<jats:p>Deflazacort and prednisone\/prednisolone are the current standard of care for patients with Duchenne muscular dystrophy (DMD) based on evidence that they improve muscle strength, improve timed motor function, delay loss of ambulation, improve pulmonary function, reduce the need for scoliosis surgery, delay onset of cardiomyopathy, and increase survival. Both have been used off-label for many years (choice dependent on patient preference, cost, and geographic location) before FDA approval of deflazacort for DMD in 2017. In this review, we compare deflazacort and prednisone\/prednisolone in terms of their key pharmacological features, relative efficacy, and safety profiles in patients with DMD. Differentiating features include lipid solubility, pharmacokinetics, changes in gene expression profiles, affinity for the mineralocorticoid receptor, and impact on glucose metabolism. Evidence from randomized clinical trials, prospective studies, meta-analyses, and post-hoc analyses suggests that patients receiving deflazacort experience similar or slower rates of functional decline compared with those receiving prednisone\/prednisolone. Regarding side effects, weight gain and behavior side effects appear to be greater with prednisone\/prednisolone than with deflazacort, whereas bone health, growth parameters, and cataracts appear worse with deflazacort.<\/jats:p>","DOI":"10.3233\/jnd-210776","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T13:25:30Z","timestamp":1655213130000},"page":"463-476","source":"Crossref","is-referenced-by-count":61,"title":["Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy"],"prefix":"10.1177","volume":"9","author":[{"given":"W. Douglas","family":"Biggar","sequence":"first","affiliation":[{"name":"University of Toronto, 15583 22nd Side Road, Georgetown, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Skalsky","sequence":"additional","affiliation":[{"name":"University of California San Diego, Rady Children\u2019s Hospital San Diego, MC, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig M.","family":"McDonald","sequence":"additional","affiliation":[{"name":"University of California Davis Health, Departments of Physical Medicine & Rehabilitation and Pediatrics, Lawrence J. Ellison Ambulatory Care Center, Sacramento, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"3","key":"10.3233\/JND-210776_ref1","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"issue":"10","key":"10.3233\/JND-210776_ref2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/ejhg.2012.301","article-title":"Newborn bloodspot screening for Duchenne muscular dystrophy: 21 years experience in Wales (UK)","volume":"21","author":"Moat","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"10.3233\/JND-210776_ref3","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"6089","key":"10.3233\/JND-210776_ref4","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/323646a0","article-title":"Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene","volume":"323","author":"Monaco","year":"1986","journal-title":"Nature323"},{"issue":"3","key":"10.3233\/JND-210776_ref5","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1083\/jcb.128.3.355","article-title":"Mechanical function of dystrophin in muscle cells","volume":"128","author":"Pasternak","year":"1995","journal-title":"J Cell Biol"},{"issue":"12","key":"10.3233\/JND-210776_ref7","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"10.3233\/JND-210776_ref9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.12688\/f1000research.13678.1","article-title":"How to prevent the next Marathon Pharmaceuticals","volume":"7","author":"David","year":"2018","journal-title":"F1000Res"},{"issue":"1","key":"10.3233\/JND-210776_ref10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: Therapeutic index, relative potency and equivalent doses versus other corticosteroids","volume":"18","author":"Parente","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"10.3233\/JND-210776_ref11","first-page":"8","article-title":"Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy","volume":"17","author":"Jensen","year":"2017","journal-title":"J Musculoskelet Neuronal Interact"},{"issue":"6","key":"10.3233\/JND-210776_ref12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/tpj.2009.22","article-title":"Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy","volume":"9","author":"Lit","year":"2009","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"10.3233\/JND-210776_ref13","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00003495-199550020-00008","article-title":"Deflazacort A review of its pharmacological properties and therapeutic efficacy.","volume":"50","author":"Markham","year":"1995","journal-title":"Drugs"},{"issue":"2","key":"10.3233\/JND-210776_ref14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/eje.0.1440087","article-title":"Clinical implications of glucocorticoid metabolism by 11beta-hydroxysteroid dehydrogenases in target tissues","volume":"144","author":"Quinkler","year":"2001","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.3233\/JND-210776_ref15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.2165\/00003088-200544010-00003","article-title":"Pharmacokinetics andpharmacodynamics of systemically administered glucocorticoids","volume":"44","author":"Czock","year":"2005","journal-title":"ClinPharmacokinet"},{"issue":"4","key":"10.3233\/JND-210776_ref16","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/0019-5154.44786","article-title":"Deflazacort versus other glucocorticoids: A comparison","volume":"53","author":"Nayak","year":"2008","journal-title":"Indian J Dermatol"},{"key":"10.3233\/JND-210776_ref17","first-page":"9","article-title":"Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and man","volume":"171","author":"Assandri","year":"1984","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.3233\/JND-210776_ref19","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.nmd.2006.01.010","article-title":"Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade","volume":"16","author":"Biggar","year":"2006","journal-title":"Neuromusc Dis"},{"issue":"4","key":"10.3233\/JND-210776_ref20","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MAJ.0b013e31828a6a01","article-title":"Glucocorticoid-induced hyperglycemia","volume":"345","author":"Kwon","year":"2013","journal-title":"Am J Med Sci"},{"issue":"4","key":"10.3233\/JND-210776_ref21","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1159\/000365892","article-title":"Hyperglycemia induced by glucocorticoids in nondiabetic patients: A meta-analysis","volume":"65","author":"Liu","year":"2014","journal-title":"Ann Nutr Metab"},{"issue":"3","key":"10.3233\/JND-210776_ref22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/eje.0.1510397","article-title":"Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: A comparison of their glucocorticoid and mineralocorticoid properties","volume":"151","author":"Grossmann","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"10.3233\/JND-210776_ref23","first-page":"3","article-title":"Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy","volume":"173","author":"Lamb","year":"2016","journal-title":"J Pediatr.207-13 e"},{"issue":"6","key":"10.3233\/JND-210776_ref24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/jamaneurol.2019.0242","article-title":"Fractures and linear growth in a nationwide cohort of boys with Duchenne muscular dystrophy with and without glucocorticoid treatment: Results from the UK NorthStar database","volume":"76","author":"Joseph","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.3233\/JND-210776_ref25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1212\/WNL.0000000000002337","article-title":"Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology","volume":"86","author":"Gloss","year":"2016","journal-title":"Neurology"},{"issue":"20","key":"10.3233\/JND-210776_ref26","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1212\/WNL.0000000000003217","article-title":"Efficacy and safety of deflazacort vs prednisone and placebo for Duchenne muscular dystrophy","volume":"87","author":"Griggs","year":"2016","journal-title":"Neurology"},{"key":"10.3233\/JND-210776_ref27","first-page":"451","article-title":"Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: A prospective cohort study","author":"McDonald","year":"1011","journal-title":"Lancet. 3919)"},{"issue":"11","key":"10.3233\/JND-210776_ref28","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.nmd.2018.07.004","article-title":"Longitudinal pulmonary function testing outcome measures in Duchenne muscular dystrophy: Long-term natural history with and without glucocorticoids","volume":"28","author":"McDonald","year":"2018","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.3233\/JND-210776_ref29","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of more than 7,000 Duchenne muscular dystrophy mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum Mutat"},{"issue":"4","key":"10.3233\/JND-210776_ref30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/JND-170280","article-title":"Clinical outcomes in Duchenne muscular dystrophy: A study of patients from the TREAT-NMD DMD global database","volume":"4","author":"Koeks","year":"2017","journal-title":"J Neuromusc Dis"},{"key":"10.3233\/JND-210776_ref31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.nmd.2019.06.381","article-title":"Modifiers of respiratory and cardiac function in the Italian Duchenne muscular dystrophy network and CINRG Duchenne natural history study","author":"Bello","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"11","key":"10.3233\/JND-210776_ref32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.nmd.2019.09.010","article-title":"Longitudinal natural history in young boys with Duchenne muscular dystrophy","volume":"29","author":"Coratti","year":"2019","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"10.3233\/JND-210776_ref33","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1177\/0883073814558120","article-title":"Corticosteroid treatments in males with Duchenne muscular dystrophy: Treatment duration and time to loss of ambulation","volume":"30","author":"Kim","year":"2015","journal-title":"Journal of Child Neurology"},{"issue":"4","key":"10.3233\/JND-210776_ref34","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.chest.2020.04.043","article-title":"Cardiorespiratory progression over 5 years and role of corticosteroids in Duchenne Muscular Dystrophy: A single-site retrospective longitudinal study","volume":"158","author":"Trucco","year":"2020","journal-title":"Chest"},{"key":"10.3233\/JND-210776_ref35","doi-asserted-by":"crossref","unstructured":"Quattrocelli M , Zelikovich AS , Jiang Z , Peek CB , Demonbreun AR , Kuntz NL , et al. Pulsed glucocorticoids enhance dystrophic muscle performance through epigenetic-metabolic reprogramming. JCI Insight. 4(24).2019;4(24)","DOI":"10.1172\/jci.insight.132402"},{"key":"10.3233\/JND-210776_ref36","doi-asserted-by":"crossref","unstructured":"Zelikovich AS , Quattrocelli M , McNally EM , Kuntz NL . Improved metabolic and bone health in boys with duchenne muscular dystrophy treated with high dose pulse weekend corticosteroids compared to daily dosing. Neurology.2020;94(15 Supplement).","DOI":"10.1212\/WNL.94.15_supplement.21"},{"issue":"3","key":"10.3233\/JND-210776_ref37","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.3233\/JND-210776_ref38","doi-asserted-by":"crossref","unstructured":"Birnkrant DJ , Bushby K , Bann CM , Apkon SD , Blackwell A , Colvin MK , et al. Diagnosis and management of Duchenne muscular dystrophy, part 3: Primary care, emergency management, psychosocial care, and transi- tions of care across the lifespan. Lancet Neurol. 2018.","DOI":"10.1016\/S1474-4422(18)30026-7"},{"issue":"12","key":"10.3233\/JND-210776_ref39","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.nmd.2012.07.010","article-title":"Fat Embolism Syndrome following minor trauma in Duchenne muscular dystrophy","volume":"22","author":"McAdam","year":"2012","journal-title":"Neuromuscular Disord"},{"key":"10.3233\/JND-210776_ref40","doi-asserted-by":"crossref","unstructured":"Kinnett K , Noritz G . The PJ Nicholoff Steroid Protocol for Duchenne and Becker muscular dystrophy and adrenal suppression. PLoS Curr. 2017;9.","DOI":"10.1371\/currents.md.d18deef7dac96ed135e0dc8739917b6e"},{"issue":"3","key":"10.3233\/JND-210776_ref41","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-170223","article-title":"Development of a new self-reportinginstrument measuring benefits and side effects of corticosteroids in Duchenne muscular dystrophy: Report from apilot study","volume":"4","author":"Hendriksen","year":"2017","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"10.3233\/JND-210776_ref42","first-page":"5","article-title":"Comparison of deflazacort and prednisone in Duchenne muscular dystrophy","volume":"6","author":"Karimzadeh","year":"2012","journal-title":"Iran J Child Neurol"},{"issue":"9","key":"10.3233\/JND-210776_ref43","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-210776_ref44","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s40267-017-0466-y","article-title":"Deflazacort in Duchenne musculardystrophy: A profile of its use in the USA","volume":"34","author":"McKeage","year":"2018","journal-title":"Drugs Ther Perspect"},{"issue":"Supplement 1","key":"10.3233\/JND-210776_ref45","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/j.nmd.2020.08.063","article-title":"Prognostic factors for loss of ability to rise from supine in Duchenne muscular dystrophy (DMD)","volume":"30","author":"Goemans","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.3233\/JND-210776_ref46","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.nmd.2012.06.354","article-title":"Bone health in boys with Duchenne Muscular Dystrophy on long-term daily deflazacort therapy","volume":"22","author":"Mayo","year":"2012","journal-title":"Neuromuscular Disord"},{"issue":"1","key":"10.3233\/JND-210776_ref47","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","article-title":"Deflazacort treatment of Duchenne muscular dystrophy","volume":"138","author":"Biggar","year":"2001","journal-title":"J Pediatr"},{"issue":"3","key":"10.3233\/JND-210776_ref48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/mus.23793","article-title":"Why short stature is beneficial in Duchenne muscular dystrophy","volume":"48","author":"Bodor","year":"2013","journal-title":"Muscle Nerve"},{"issue":"Supplement 1","key":"10.3233\/JND-210776_ref49","first-page":"S142","article-title":"Duchenne muscular dystrophy: Do boys with a shorter stature maintain ambulation longer?","volume":"5","author":"Labove","year":"2018","journal-title":"J Neuromusc Dis"},{"issue":"3","key":"10.3233\/JND-210776_ref50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaapos.2018.01.017","article-title":"Cataract development associated with long-term glucocorticoid therapy in Duchenne muscular dystrophy patients","volume":"22","author":"Rice","year":"2018","journal-title":"J AAPOS"},{"issue":"5","key":"10.3233\/JND-210776_ref51","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/mus.26191","article-title":"Deflazacort versus prednisone\/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial","volume":"58","author":"Shieh","year":"2018","journal-title":"Muscle Nerve"},{"issue":"1","key":"10.3233\/JND-210776_ref52","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/mus.26736","article-title":"Deflazacort versus prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials","volume":"61","author":"McDonald","year":"2020","journal-title":"Muscle Nerve"},{"issue":"18","key":"10.3233\/JND-210776_ref53","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2217\/cer-2021-0018","article-title":"Meta-analyses of deflazacort versus prednisone\/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy","volume":"10","author":"Shieh","year":"2021","journal-title":"J Comp Eff Res"},{"key":"10.3233\/JND-210776_ref55","doi-asserted-by":"crossref","unstructured":"Sun C , Shen L , Zhang Z , Xie X . Therapeutic strategies for Duchenne muscular dystrophy: An update. Genes (Basel). 2020;11(8).","DOI":"10.3390\/genes11080837"},{"issue":"4","key":"10.3233\/JND-210776_ref56","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.nmd.2020.02.007","article-title":"Beyond ambulation: Measuringphysical activity in youth with Duchenne muscular dystrophy","volume":"30","author":"Killian","year":"2020","journal-title":"Neuromuscul Disord."},{"issue":"5","key":"10.3233\/JND-210776_ref57","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/WCO.0000000000000243","article-title":"Duchenne muscular dystrophy: Clinical trials and emerging tribulations","volume":"28","author":"Shieh PB","year":"2015","journal-title":"Curr Opin Neurol"},{"issue":"2","key":"10.3233\/JND-210776_ref58","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.dsx.2017.08.006","article-title":"Energy expenditure, body composition, and prevalence of metabolic disorders in patients with Duchenne muscular dystrophy","volume":"12","author":"Saure","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"10.3233\/JND-210776_ref59","doi-asserted-by":"crossref","unstructured":"Landon SN , Padikkala J , Horwitz LI . Defining value in health care: A scoping review of the literature. Int J Qual Health Care. 2021;33(4).","DOI":"10.1093\/intqhc\/mzab140"},{"issue":"2","key":"10.3233\/JND-210776_ref60","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamaneurol.2017.3704","article-title":"Deflazacort-New Costs of an Old Medicine","volume":"75","author":"Chrzanowski","year":"2018","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.3233\/JND-210776_ref61","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0883073810371004","article-title":"Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: Implications for management","volume":"25","author":"Moxley","year":"2010","journal-title":"J Child Neurol"},{"issue":"9","key":"10.3233\/JND-210776_ref64","first-page":"A563","article-title":"Diagnosis of patients with Duchenne muscular dystrophy (DMD): Results from a global survey of healthcare providers from nine countries","volume":"20","author":"Narayanan","year":"2017","journal-title":"Value in Health"},{"key":"10.3233\/JND-210776_ref65","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2017.04.008","article-title":"Developing standardized corticosteroid treatment for Duchenne muscular dystrophy","volume":"58","author":"Guglieri","year":"2017","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.3233\/JND-210776_ref66","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.pmr.2012.08.003","article-title":"Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy","volume":"23","author":"Hoffman","year":"2012","journal-title":"Phys Med Rehab Clin N Am"},{"key":"10.3233\/JND-210776_ref67","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.phrs.2018.09.007","article-title":"Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug","volume":"136","author":"Conklin","year":"2018","journal-title":"Pharmacol Res"},{"issue":"7","key":"10.3233\/JND-210776_ref68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41582-019-0203-3","article-title":"Therapeutic developments for Duchenne muscular dystrophy","volume":"15","author":"Verhaart","year":"2019","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-210776","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:59Z","timestamp":1777506599000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-210776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,1]]},"references-count":62,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jnd-210776","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,1]]}}}